ArticleRenal failure2025
Efficacy and safety of telitacicept in IgA nephropathy: a real-world study.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Telitacicept for IgA nephropathy: a systematic review and meta-analysis of observational studies.Frontiers in medicine · 2026Pooled it
- Dual BAFF/APRIL inhibition with telitacicept in systemic lupus erythematosus and IgA nephropathy: pharmacological rationale, clinical efficacy, and safety on female fertility preservation.Frontiers in pharmacology · 2026Pooled it
- Immune-mediated renal injury and cardiometabolic risk in IgA nephropathy: clinical evidence on telitacicept from a scoping review.Frontiers in nutrition · 2026Pooled it
- Efficacy and safety of BAFF/APRIL dual antagonists in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.BMC nephrology · 2025Pooled it
- Research on the safety and efficacy of telitacicept in the treatment of IgA nephropathy in children.Renal failure · 2026Article
- Observation on the short-term efficacy of telitacicept in the treatment of primary IgA nephropathy.International urology and nephrology · 2026Article
- Recent Advancements in the Therapeutic Landscape of IgA Nephropathy and the Impact of Dual Blockers: Telitacicept.Kidney medicine · 2026Review
- Telitacicept for childhood HSPN: A prospective self-controlled study.Clinical rheumatology · 2026Article
- Real-World Comparative Evidence for Telitacicept, Glucocorticoids, and Nefecon in IgA Nephropathy: Clinical Value and Interpretive Considerations [Letter].Drug design, development and therapy · 2026Article
- Real-world study of telitacicept in the treatment of IgA nephropathy.Frontiers in immunology · 2026Article
- Mechanistic Insights and Therapeutic Advances of Anti-Inflammatory Biologics in Immune-Mediated Glomerulonephritis: A Narrative Review.Journal of inflammation research · 2026Review
- Case Report: Successful telitacicept treatment for IgA nephropathy with stage 4 chronic kidney disease and acute renal failure.Frontiers in immunology · 2026Article
- Short-term changes in clinical parameters associated with telitacicept in pediatric IgA nephropathy: a single-center self-controlled observational study.Frontiers in pediatrics · 2026Article
- Efficacy and safety of telitacicept combined with immunosuppressive therapy for IgA nephropathy: a retrospective multicenter cohort study.Frontiers in immunology · 2026Observational
- Efficacy and safety of Telitacicept in IgA nephropathy and its impact on urinary Gd-IgA1: insights from a real-world study.Frontiers in immunology · 2026Article
- Efficacy and safety of telitacicept in the treatment of immunoglobulin a nephropathy: a real-world, single-center, retrospective study.BMC nephrology · 2025Article
- Telitacicept versus mycophenolate mofetil in IgA nephropathy: a real-world comparative study of efficacy, renal outcomes and safety.Clinical kidney journal · 2025Article
- Efficacy and Safety of Telitacicept and Mycophenolate Mofetil in the Treatment of Neuromyelitis Optica Spectrum Disorders.Annals of Indian Academy of Neurology · 2025Article
- Efficacy and safety of telitacicept in the treatment of IgA nephropathy: a single-center, real-world study.Frontiers in pharmacology · 2025Article
- Preliminary analysis of short-term real-world outcomes of telitacicept in high-risk IgA nephropathy.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIgA nephropathy (IgAN) is the most common primary glomerular disease in the world, and specific therapeutic methods for IgAN are limited. Telitacicept is a humanized fusion protein composed of a transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor and human IgG.
aimTo evaluate the efficacy and safety of telitacicept in adult patients with IgAN in a real-world study.
methodsBiopsy-proven IgAN patients with 24-hour proteinuria greater than 0.5 g/d who received 240 mg telitacicept weekly were recruited for this study and 1:1:1 matched with patients who received supportive treatment only or immunosuppressive treatment by propensity score matching. The primary outcome was the change from baseline in 24-hour proteinuria over the 3-month follow-up.
resultsTwenty-one patients in each group were enrolled. Telitacicept reduced median proteinuria by 0.72 g/d (54.6%) from baseline, compared with a reduction of 0.18 g/d (20%) in the supportive treatment group and 1.12 g/d (72.1%) in the immunosuppressive treatment group. Preserved eGFR levels were observed in the telitacicept group, whereas eGFR levels decreased in the other two groups. No serious adverse events were observed in the telitacicept treatment group.
conclusionTelitacicept may be an effective treatment for IgAN patients by reducing proteinuria and preserving eGFR, and showed a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.